Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma (MCLPIII)
Sponsor: Cancer Research UK
A PHASE2/PHASE3 clinical study on Lymphoma, this trial is completed. The trial is conducted by Cancer Research UK and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
Status: Unknown Status → Completed · Phase: PHASE3 → PHASE2_PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Research UK
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .